Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;154(3):353-364.
doi: 10.1007/s11060-021-03834-3. Epub 2021 Sep 9.

Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation

Andrés F Cardona #  1   2   3   4 , Daniel Jaramillo-Velásquez #  5 , Alejandro Ruiz-Patiño #  6   7 , Carolina Polo  6   7 , Enrique Jiménez  5 , Fernando Hakim  5 , Diego Gómez  5 , Juan Fernando Ramón  5 , Hernando Cifuentes  8 , Juan Armando Mejía  5 , Fernando Salguero  5 , Camila Ordoñez  6   7 , Álvaro Muñoz  9 , Sonia Bermúdez  10 , Nicolas Useche  10 , Diego Pineda  11 , Luisa Ricaurte  12 , Zyanya Lucia Zatarain-Barrón  13 , July Rodríguez  6   7 , Jenny Avila  6   7 , Leonardo Rojas  14   7   15 , Elvira Jaller  6   7 , Carolina Sotelo  6   7 , Juan Esteban Garcia-Robledo  16 , Nicolas Santoyo  6   7 , Christian Rolfo  17 , Rafael Rosell  18 , Oscar Arrieta  13
Affiliations

Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation

Andrés F Cardona et al. J Neurooncol. 2021 Sep.

Abstract

Background: Amplification of EGFR and its active mutant EGFRvIII are common in glioblastoma (GB). While EGFR and EGFRvIII play critical roles in pathogenesis, targeted therapy with EGFR-tyrosine kinase inhibitors or antibodies has shown limited efficacy. To improve the likelihood of effectiveness, we targeted adult patients with recurrent GB enriched for simultaneous EGFR amplification and EGFRvIII mutation, with osimertinib/bevacizumab at doses described for non-small cell lung cancer.

Methods: We retrospectively explored whether previously described EGFRvIII mutation in association with EGFR gene amplification could predict response to osimertinib/bevacizumab combination in a subset of 15 patients treated at recurrence. The resistance pattern in a subgroup of subjects is described using a commercial next-generation sequencing panel in liquid biopsy.

Results: There were ten males (66.7%), and the median patient's age was 56 years (range 38-70 years). After their initial diagnosis, 12 patients underwent partial (26.7%) or total resection (53.3%). Subsequently, all cases received IMRT and concurrent and adjuvant temozolomide (TMZ; the median number of cycles 9, range 6-12). The median follow-up after recurrence was 17.1 months (95% CI 12.3-22.6). All patients received osimertinib/bevacizumab as a second-line intervention with a median progression-free survival (PFS) of 5.1 months (95% CI 2.8-7.3) and overall survival of 9.0 months (95% CI 3.9-14.0). The PFS6 was 46.7%, and the overall response rate was 13.3%. After exposure to the osimertinib/bevacizumab combination, the main secondary alterations were MET amplification, STAT3, IGF1R, PTEN, and PDGFR.

Conclusions: While the osimertinib/bevacizumab combination was marginally effective in most GB patients with simultaneous EGFR amplification plus EGFRvIII mutation, a subgroup experienced a long-lasting meaningful benefit. The findings of this brief cohort justify the continuation of the research in a clinical trial. The pattern of resistance after exposure to osimertinib/bevacizumab includes known mechanisms in the regulation of EGFR, findings that contribute to the understanding and targeting in a stepwise rational this pathway.

Keywords: Amplification; Bevacizumab; EGFR; Glioblastoma; Mutation; Osimertinib; Tyrosine kinase inhibitor.

PubMed Disclaimer

References

    1. Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. https://doi.org/10.1093/neuonc/noab106 - DOI - PubMed - PMC
    1. Weller M, van den Bent M, Preusser M et al (2020) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18(3):170–186. https://doi.org/10.1038/s41571-020-00447-z - DOI - PubMed - PMC
    1. McNeill KA (2016) Epidemiology of brain tumors. Neurol Clin 34(4):981–998. https://doi.org/10.1016/j.ncl.2016.06.014 - DOI - PubMed
    1. Chen W, Wang Y, Zhao B et al (2021) Optimal therapies for recurrent glioblastoma: a bayesian network meta-analysis. Front Oncol 29(11):641878. https://doi.org/10.3389/fonc.2021.641878 - DOI
    1. McBain C, Lawrie TA, Rogozińska E et al (2021) Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. Cochrane Database Syst Rev (1). Art. No.: CD013579. https://doi.org/10.1002/14651858.CD013579.pub2

LinkOut - more resources